Caribou Biosciences (NASDAQ:CRBU) Stock Price Down 2.3% - Here's Why

Key Points

• CRBU shares fell 2.3% to $2.08 mid-day, with ~1.14 million shares traded—about 21% below the stock's average daily volume.
• Analysts are mixed but generally positive: the consensus rating is a "Moderate Buy" with an average price target of $8.00 (one Strong Buy, two Buy, one Sell).
• Caribou is a clinical‑stage CRISPR gene‑editing developer with a market cap of ~$205M, negative earnings and a very large net loss, though it beat last quarter's EPS and revenue estimates (EPS -$0.28 vs -$0.33 est; revenue $3.94M).

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report)'s stock price was down 2.3% during mid-day trading on Tuesday . The stock traded as low as $2.06 and last traded at $2.08. Approximately 1,135,224 shares changed hands during trading, a decline of 21% from the average daily volume of 1,439,700 shares. The stock had previously closed at $2.13.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CRBU shares. Truist Financial upgraded shares of Caribou Biosciences to a "strong-buy" rating in a report on Wednesday, March 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Caribou Biosciences in a report on Monday, April 20th. Finally, HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Caribou Biosciences in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $8.00.

Caribou Biosciences Stock Down 2.3%

The stock's 50-day moving average price is $1.96 and its 200-day moving average price is $1.90. The company has a market capitalization of $205.25 million, a price-to-earnings ratio of -1.31 and a beta of 2.46.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its earnings results on Thursday, March 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.05. Caribou Biosciences had a negative net margin of 1,327.40% and a negative return on equity of 78.40%. The company had revenue of $3.94 million for the quarter, compared to analyst estimates of $1.96 million. On average, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.3 EPS for the current year.

Institutional Investors Weigh In On Caribou Biosciences

Several large investors have recently made changes to their positions in CRBU. AQR Capital Management LLC increased its position in shares of Caribou Biosciences by 741.6% during the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock worth $480,000 after acquiring an additional 463,391 shares in the last quarter. Acadian Asset Management LLC bought a new position in Caribou Biosciences in the first quarter valued at $61,000. Creative Planning bought a new position in Caribou Biosciences in the second quarter valued at $25,000. XTX Topco Ltd bought a new position in Caribou Biosciences in the second quarter valued at $133,000. Finally, Jane Street Group LLC grew its position in Caribou Biosciences by 64.7% in the second quarter. Jane Street Group LLC now owns 483,610 shares of the company's stock valued at $609,000 after purchasing an additional 189,923 shares in the last quarter. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.